Coreline Soft Receives FDA Clearance for Aortic CT Analysis Software
Oct 23, 2026
Healthcare
Carvolix Reports Successful Postmarketing Results for TAVIPILOT AI Software
May 4, 2026
Carvolix announced positive results from its SAITO clinical program evaluating the TAVIPILOT AI software for Transcatheter Aortic Valve Implantation procedures, achieving full procedural success across studies in France and Australia.
Carvolix announced the completion of its SAITO postmarketing clinical program evaluating the TAVIPILOT software used during Transcatheter Aortic Valve Implantation procedures. The program included three studies involving 30 patients across France and Australia.
The company reported a 100 percent procedural success rate and high clinician satisfaction with the software. TAVIPILOT assists medical teams in precise positioning of heart valves during implantation and has received clearance for commercial use in the United States.
The positive results from the SAITO program support broader clinical adoption of TAVIPILOT as a guidance tool for valve placement. Carvolix also published its 2025 Universal Registration Document and confirmed an extension of its cash runway through additional funding.
We hope you enjoyed this article
Consider subscribing to one of our newsletters like Life AI Weekly or Daily AI Brief.
Also, consider following us on social media:
More from Life Sciences
Nov 13 Bracco and Avicenna.AI win FDA clearance for AI that flags brain aneurysms on CT scans Nov 13 Zus Health raises $33 million to build the data layer for healthcare AI Nov 13 Google DeepMind releases AlphaGenome 2 to predict DNA variant effects in specific cell types Nov 13 Taiwan hospital accelerator T+ MedIC names AI ECG and CT screening tools as first winners Nov 13 Sheinbaum meets OpenAI president Greg Brockman on AI in Mexican healthcareFree newsletter
Life AI Weekly
Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.
Industry analysis
2025 Global Business Services Agenda: Gen AI Takes Center Stage
The Hackett Group
This industry analysis by The Hackett Group explores the transformative impact of generative artificial intelligence (Gen AI) on global business services (GBS) in 2025. The study highlights the shift from exploration to acceleration of Gen AI initiatives, with 89% of executives advancing these projects to improve customer satisfaction, innovate products, and reduce costs. The report also discusses the challenges and strategies for successful Gen AI adoption, emphasizing the need for a technology-enabled operating model and the importance of reskilling the workforce.
Read moreYou may also like
Adsilico Raises £10 Million for Virtual Medical Device Testing
Oct 27, 2026
Healthcare
FDA Clears RIVANNA BoneEnhance Software for Accuro XV
Oct 22, 2026
Healthcare
Bracco and Avicenna.AI win FDA clearance for AI that flags brain aneurysms on CT scans
Nov 13, 2026
Healthcare
Atlas Bio raises $12.5 million for virtual drug trials
Oct 27, 2026
Healthcare
SimBioSys Gets FDA Clearance for AI Breast Cancer Recurrence Tool
Oct 15, 2026
Biotech
Free, six days a week
Daily AI Brief: the AI news that matters, in your inbox.